Veterinary Orthobiologics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product (Stem Cells, Platelet-rich Plasma (PRP), Other), By Animal (Canine, Equine, Others), By Application (Osteoarthritis, Degenerative Joint Disease, Other), By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others), By End User (Veterinary Hospitals, Veterinary Clinics, Others), By Region & Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 689.85 Million

Market Size (2029)

USD 1106.37 Million

CAGR (2024-2029)

8.15%

Fastest Growing Segment

Platelet-Rich Plasma (PRP)

Largest Market

North America

Market Overview

Global Veterinary Orthobiologics Market was valued at USD 689.85 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2029. The global market for managing musculoskeletal disorders is experiencing rapid expansion, primarily due to the rising prevalence of these conditions. This growth is fueled by several key factors, including demographic shifts, advancements in technology, and evolving healthcare practices. Notably, the increase in the elderly population is directly linked to a higher incidence of musculoskeletal disorders, thereby driving demand for related therapies and treatments.

Key trends contributing to market growth include the adoption of orthobiologics, the expansion of veterinary services, and increased investment in research and development. However, the market also faces challenges such as high treatment costs, regulatory hurdles, and variability in standardization. A thorough understanding of these dynamics offers valuable insights into the global market influenced by the escalating incidence of musculoskeletal disorders.

Key Market Drivers

Rising Incidence of Musculoskeletal Disorders

Musculoskeletal disorders, such as arthritis, hip dysplasia, cruciate ligament injuries, and tendonitis, are increasingly common among both companion animals and livestock. The growing prevalence of these conditions creates a heightened demand for effective treatment options. Orthobiologic therapies, which include Platelet-Rich Plasma (PRP), stem cell therapy, and bone grafts, offer advanced solutions for managing these disorders, driving their adoption in veterinary practice. As musculoskeletal disorders become more prevalent, there is a growing preference for non-surgical treatment options that provide effective relief and improve quality of life. Orthobiologics offer minimally invasive alternatives to traditional surgery, addressing the need for less invasive and more efficient therapeutic options. This shift towards non-surgical treatments fuels market growth by making orthobiologic therapies more appealing to both veterinarians and pet owners. The increasing incidence of musculoskeletal disorders necessitates the development and availability of a diverse range of treatment options. Orthobiologic therapies provide a variety of solutions tailored to different types of musculoskeletal issues and animal species. This diversity in treatment options helps address the specific needs of animals suffering from various disorders, further driving the growth of the orthobiologics market.

The rising incidence of musculoskeletal disorders has led to a greater emphasis on early diagnosis and preventive care in veterinary medicine. Veterinarians are increasingly adopting orthobiologic therapies as part of proactive treatment plans aimed at managing and mitigating the progression of musculoskeletal conditions before they become severe. This focus on early intervention promotes the use of orthobiologics and contributes to market growth. Advancements in diagnostic technologies enable earlier and more accurate detection of musculoskeletal disorders. Early diagnosis allows for timely intervention with orthobiologic treatments, which can prevent the escalation of conditions and enhance treatment outcomes. The ability to diagnose and address issues at an early stage drives demand for orthobiologic therapies and supports market expansion. As the incidence of musculoskeletal disorders rises, there is increased awareness among veterinarians about the benefits of orthobiologic treatments. Continued education and training in advanced treatment options encourage veterinarians to incorporate orthobiologics into their practice, thereby driving market growth.

The rising prevalence of musculoskeletal disorders leads to higher expenditure on veterinary care. Pet owners and livestock managers are willing to invest in advanced treatments, including orthobiologics, to manage and alleviate the impact of these disorders. This increased spending supports market growth by creating a larger consumer base for orthobiologic products and services. The demand for orthobiologic treatments driven by the rising incidence of musculoskeletal disorders encourages the establishment and expansion of veterinary practices specializing in orthopedics and regenerative medicine. The growth of these specialized practices enhances the availability and accessibility of orthobiologic therapies, contributing to market expansion. The growing incidence of musculoskeletal disorders stimulates investment in research and development focused on improving orthobiologic treatments. Pharmaceutical companies, biotechnology firms, and research institutions are motivated to develop new and enhanced therapies to address the needs of a growing patient population. This R&D investment drives innovation and supports the growth of the orthobiologics market.

Increasing Pet Ownership and Humanization of Pets

The rise in pet ownership globally results in a larger population of pets requiring veterinary care. As the number of pets increases, so does the incidence of various health issues, including musculoskeletal disorders. This growing pet population translates into a higher demand for effective treatments, including orthobiologics, to manage and alleviate these conditions. With more households owning pets, the market for veterinary products and services, including orthobiologics, expands accordingly. The larger pet owner base creates a broader market for advanced therapeutic options, driving growth in the veterinary orthobiologics sector. As pet ownership increases, so does the expenditure on pet healthcare. Pet owners are increasingly willing to invest in advanced medical treatments to ensure the well-being of their animals. This willingness to spend on high-quality care, including orthobiologic treatments, boosts market growth by increasing demand for these advanced therapies.

The trend of treating pets as family members—often referred to as the humanization of pets—leads to a heightened focus on their health and quality of life. Pet owners who view their animals as integral parts of their families are more likely to seek out advanced and comprehensive medical treatments for their pets, including orthobiologics. As pets are increasingly viewed as family members, there is a growing demand for advanced medical treatments that are comparable to human healthcare. Orthobiologic therapies, which offer cutting-edge solutions for managing musculoskeletal disorders, align with this demand. The humanization trend drives pet owners to explore and invest in these sophisticated treatments to provide the best possible care for their pets. The emotional bond between pet owners and their pets drives a strong desire to alleviate any suffering and improve the quality of life of their animals. This emotional connection motivates pet owners to opt for advanced treatments, such as orthobiologics, to address musculoskeletal disorders and enhance their pets' comfort and mobility.

The humanization of pets also fosters an increased emphasis on preventive and proactive care. Pet owners and veterinarians are more inclined to adopt early intervention strategies to manage musculoskeletal disorders before they progress to more severe stages. Orthobiologic therapies, which can be used to manage and mitigate the effects of these conditions early on, align with this proactive approach. The growing focus on preventive care and the humanization of pets leads to the development and expansion of veterinary services that cater to advanced medical needs. Veterinary clinics and hospitals are increasingly offering specialized services, including orthobiologic treatments, to meet the demands of conscientious pet owners seeking comprehensive care for their pets. The humanization trend also drives increased awareness and education about advanced treatment options among pet owners. As pet owners become more informed about the benefits of orthobiologic therapies, they are more likely to seek out these treatments for their pets. This increased awareness contributes to the growing adoption of orthobiologic solutions and market expansion.

Technological Advancements in Regenerative Medicine

Recent advancements in stem cell therapy, including improvements in cell extraction, processing, and application techniques, have enhanced the efficacy and safety of treatments for musculoskeletal disorders. New methods for isolating and expanding stem cells ensure higher potency and better integration into damaged tissues. These improvements lead to more effective treatments, which drive demand for orthobiologics. Platelet-Rich Plasma (PRP) therapy has seen significant technological progress, such as the development of automated systems for preparing PRP with higher concentration and quality. Enhanced PRP formulations lead to improved outcomes in treating conditions like arthritis and ligament injuries. The increased effectiveness of PRP therapy boosts its adoption and market growth. Advancements in tissue engineering, such as the development of biomaterials and scaffolds that promote tissue regeneration, support the creation of more effective orthobiologic treatments. These innovations enable the repair and regeneration of damaged musculoskeletal tissues, driving the adoption of orthobiologics as a preferred treatment option.

Technological advancements have broadened the range of conditions that can be effectively treated with orthobiologics. Innovations such as gene editing and bioengineered tissues allow for the development of therapies that address a wider variety of musculoskeletal disorders, from joint degeneration to complex fractures. This expansion of treatment indications increases the market’s potential and drives growth. Technological progress enables the customization and personalization of orthobiologic treatments based on individual patient needs. Personalized therapies, which are tailored to the specific condition and biological profile of the animal, offer enhanced effectiveness and reduced risks. The ability to customize treatments drives demand for advanced orthobiologic solutions and contributes to market growth. Advancements in regenerative medicine facilitate the development of combination therapies that integrate orthobiologics with other treatment modalities. For example, combining stem cell therapy with PRP or surgical interventions can enhance overall treatment outcomes. The availability of combination therapies expands the market and drives the adoption of orthobiologics.

Technological innovations often lead to more efficient production processes and reduced costs of orthobiologic products. Advances in manufacturing and processing technologies help lower the costs associated with stem cell and PRP therapies, making these treatments more accessible to a broader range of veterinary practices and pet owners. Reduced costs contribute to increased adoption and market growth. Technological advancements in diagnostic and monitoring tools enhance the ability to assess and track the progress of musculoskeletal disorders and the effectiveness of orthobiologic treatments. Better diagnostic tools lead to more accurate treatment planning and monitoring, which supports the adoption of orthobiologics and drives market growth. As technology advances, more veterinary practices are equipped with the latest orthobiologic treatment technologies. The increased availability of these advanced treatments in veterinary clinics and hospitals drives market growth by making orthobiologic therapies more widely accessible to pet owners and livestock managers.


Download Free Sample Report

Key Market Challenges

High Cost of Treatments

Orthobiologic treatments, such as stem cell therapy and Platelet-Rich Plasma (PRP), are often associated with high costs due to the complex and specialized nature of the procedures and the materials used. The expense of harvesting, processing, and administering these treatments can be prohibitive for many pet owners and livestock managers, limiting market access and adoption. Veterinary insurance coverage for advanced treatments like orthobiologics is often limited or non-existent. Many pet insurance plans do not cover the full range of orthobiologic therapies, which can deter owners from pursuing these treatments due to out-of-pocket expenses. This lack of insurance support impacts the overall market potential and accessibility of orthobiologic solutions.

Small and mid-sized veterinary practices may struggle to afford the initial investment in orthobiologic technologies and equipment. This economic constraint can restrict the availability of these treatments, particularly in less affluent regions, and limit the growth of the market.

Regulatory and Approval Challenges

The regulatory landscape for veterinary orthobiologics can be complex and varied across different regions. Navigating the regulatory requirements for approval and commercialization of these products involves rigorous testing, documentation, and compliance processes. This complexity can delay the introduction of new products and increase the cost of bringing them to market. There is significant variability in regulatory standards and requirements for orthobiologic treatments across countries. Different regions may have divergent guidelines for product safety, efficacy, and quality, creating challenges for companies seeking to market their products internationally. This lack of uniformity can hinder market expansion and increase operational challenges for global companies.

The absence of standardized protocols and guidelines for the use of orthobiologics in veterinary medicine can lead to inconsistencies in treatment outcomes and clinical practices. This lack of standardization can impact the credibility and acceptance of orthobiologic therapies among veterinarians and pet owners.

Limited Awareness and Education

Not all veterinarians are fully aware of the benefits and applications of orthobiologic treatments. Limited knowledge and familiarity with these advanced therapies can lead to underutilization and reluctance to adopt new treatment options. This gap in awareness can impede the growth of the market as veterinarians play a crucial role in recommending and administering orthobiologic therapies.

There is a need for more comprehensive educational resources and training programs to inform veterinary professionals about the latest advancements in orthobiologics. Insufficient education and professional development opportunities can hinder the effective implementation of these treatments and limit market growth. The general public, including pet owners, may lack a clear understanding of the benefits and effectiveness of orthobiologic treatments. Misconceptions or insufficient information about these therapies can result in lower demand and adoption rates. Efforts to educate pet owners and enhance public awareness are essential for driving market growth.

Key Market Trends

Advancements in Regenerative Medicine and Technology

Recent advancements in regenerative medicine, particularly in the development of new orthobiologic products such as stem cell therapies, Platelet-Rich Plasma (PRP), and tissue engineering, are significantly driving market growth. Innovations in these areas enhance the efficacy and safety of treatments, offering improved outcomes for a range of musculoskeletal conditions in animals. The integration of advanced technologies, such as automated PRP systems, 3D bioprinting, and gene editing, is transforming the landscape of veterinary orthobiologics. These technologies enable the creation of more precise, effective, and personalized treatment solutions. The increased availability and adoption of these technologies in veterinary practices are expected to boost market growth.

Ongoing research and development efforts are crucial in advancing orthobiologic therapies. Significant investments in R&D by pharmaceutical companies, research institutions, and biotechnology firms are leading to the development of novel products and treatment protocols. As these innovations come to market, they will drive further growth and diversification in the veterinary orthobiologics sector.

Growing Awareness and Acceptance Among Pet Owners

The trend towards the humanization of pets has led to a greater emphasis on providing high-quality, advanced medical care for animals. Pet owners increasingly view their pets as family members and are willing to invest in innovative treatments to improve their pets' health and quality of life. This shift is driving demand for orthobiologic treatments that offer advanced solutions for injuries and degenerative diseases. Educational initiatives by veterinary associations, pet care organizations, and media have increased awareness about the benefits of orthobiologic therapies. Pet owners are becoming more informed about the advantages of treatments such as PRP and stem cell therapy, which contributes to higher adoption rates and market growth.

The expansion of veterinary services and clinics, including those specializing in orthobiologics, is making these treatments more accessible to pet owners. As more veterinary practices incorporate advanced orthobiologic therapies into their service offerings, the market is expected to grow as a result of increased availability and accessibility.

Increasing Prevalence of Musculoskeletal Disorders

The increasing prevalence of musculoskeletal disorders, such as arthritis, ligament injuries, and hip dysplasia, in both companion animals and livestock is a major driver of the veterinary orthobiologics market. Factors such as aging pet populations, sedentary lifestyles, and breed-specific genetic predispositions contribute to the rising incidence of these conditions. The growing incidence of orthopedic conditions creates a strong demand for effective, non-surgical treatment options. Orthobiologic therapies, which offer benefits such as accelerated healing, reduced inflammation, and improved joint function, are increasingly sought after as alternatives to traditional treatments.

There is a growing trend towards proactive and preventive veterinary care, with a focus on early intervention and management of orthopedic conditions. Veterinarians are increasingly using orthobiologic treatments as part of comprehensive care plans to address and manage musculoskeletal issues before they become severe, driving market demand.

Segmental Insights

Product Insights

Based on the category of Product, the Platelet-Rich Plasma (PRP) segment emerged as the dominant in the global market for Veterinary Orthobiologics in 2023. PRP therapy utilizes a concentration of platelets derived from the animal's blood, rich in growth factors that stimulate healing and tissue regeneration. This makes PRP highly effective in treating a range of musculoskeletal conditions, including tendonitis, osteoarthritis, and ligament injuries, ensuring quicker recovery times and improved outcomes. PRP procedures are minimally invasive, involving simple blood draws and injections. This reduces the risk of complications and promotes faster recovery compared to surgical interventions. The simplicity and safety of PRP treatments make them an attractive option for both pet owners and veterinarians. Continuous advancements in PRP preparation technologies have enhanced the efficacy and consistency of treatments. Innovations such as automated PRP centrifuges and advanced concentration techniques ensure high-quality PRP formulations, which are crucial for successful therapeutic outcomes.

Technological improvements have also made PRP systems more accessible to veterinary clinics of various sizes. Portable PRP kits and systems allow veterinarians to prepare and administer PRP treatments in-house, eliminating the need for external laboratory services and reducing overall treatment costs. Increasing awareness among pet owners and livestock producers about the benefits of PRP therapy drives demand. Educational efforts by veterinary associations, coupled with positive clinical outcomes, have led to broader acceptance and adoption of PRP treatments. The versatility of PRP in treating a wide range of conditions across different animal species, including horses, dogs, and cats, enhances its appeal. PRP is used not only in orthopedics but also in wound healing and dermatological applications, expanding its market potential. These factors are expected to drive the growth of this segment.

Animal Insights

The canine segment is projected to experience rapid growth during the forecast period. Dogs are among the most popular pets globally, with a significant percentage of households owning one or more dogs. This high rate of pet ownership naturally drives demand for veterinary services, including orthobiologic treatments, to address various musculoskeletal conditions. The increasing trend of treating pets as family members has led to a greater willingness among pet owners to invest in advanced medical treatments. This humanization trend is particularly strong in the canine segment, where owners are keen to provide the best possible care for their dogs, including orthobiologics for injuries and degenerative diseases.

The field of veterinary medicine has seen significant advancements in the development of orthobiologic treatments tailored specifically for canines. These treatments, including stem cell therapy, Platelet-Rich Plasma (PRP), and bone graft substitutes, have proven highly effective in promoting healing and enhancing the quality of life for dogs suffering from orthopedic conditions. The rise of specialized veterinary practices focused on orthopedics and regenerative medicine has made advanced treatments more accessible to dog owners. These practices often offer cutting-edge orthobiologic therapies, contributing to the growth and dominance of the canine segment. Dogs are prone to various orthopedic issues such as arthritis, ligament injuries (e.g., cranial cruciate ligament tears), and hip dysplasia. The prevalence of these conditions creates a substantial and consistent demand for effective treatment options, including orthobiologics. These factors collectively contribute to the growth of this segment.


Download Free Sample Report

Regional Insights

North America emerged as the dominant in the global Veterinary Orthobiologics market in 2023, holding the largest market share in terms of value. North America boasts one of the highest per capita healthcare expenditures in the world, which translates into substantial investment in veterinary care. Pet owners and livestock producers in the region are more willing to spend on advanced treatments for animals, driving demand for orthobiologic products. The region has a well-established veterinary infrastructure, including numerous veterinary clinics, hospitals, and research institutions. This infrastructure supports the widespread availability and adoption of advanced veterinary treatments, including orthobiologics.

North America is a hub for technological innovation and research in the field of veterinary medicine. Leading universities and research institutions conduct extensive studies on veterinary orthobiologics, fostering continuous advancements and new product developments. This innovation pipeline ensures a steady flow of cutting-edge solutions to the market. The presence of major pharmaceutical and biotechnology companies in the region facilitates strategic partnerships and collaborations. These collaborations often lead to the development and commercialization of new orthobiologic products, further strengthening the market.

Recent Developments

  • In May 2024 - VetStem, Inc., a leader in regenerative veterinary medicine, has announced a major advancement with the filing of a Patent Cooperation Treaty (PCT) application for its PrecisePRP platform. This groundbreaking technology delivers an off-the-shelf, freeze-dried platelet-rich plasma (PRP) product. This innovative solution marks a significant leap in orthopedic medicine, offering the first standardized, pre-packaged PRP dose for veterinary use. Furthermore, VetStem plans to leverage this innovation for human applications through its exclusive licensee, Personalized Stem Cells, Inc.
  • In April 2023, Researchers at LSU have developed a groundbreaking syringe designed to temporarily store adult stem cells, allowing for their delivery and administration from a single device. This innovation provides a significant enhancement for physicians and veterinarians, improving the efficacy of treatments for tendon injuries.
  • In October 2023, Athersys, Inc., a leading company in cell therapy and regenerative medicine known for its MultiStem (invimestrocel) and Multipotent Adult Progenitor Cell (MAPC®) technologies, has announced a licensing agreement with Ardent Animal Health. Ardent, a privately held veterinary biotechnology firm, specializes in developing regenerative medicine and cancer therapies for animals.

Key Market Players

  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Ardent Animal Health
  • Enso Discoveries, LLC
  • VetStem, Inc
  • MEDREGO LLC
  • Arthrex, Inc.
  • Hilltop Biosciences
  • Enovis Corporation
  • Dechra Pharmaceuticals Limited

By Product

By Animal

By Application

By End User

By Delivery Mode

By Region
  • Stem Cells
  • Platelet-rich Plasma (PRP)
  • Other
  • Canine
  • Equine
  • Others
  • Osteoarthritis
  • Degenerative Joint Disease
  • Other
  • Veterinary Hospitals
  • Veterinary Clinics
  • Others
  • Intra-muscular/Intra-lesional
  • Intra-articular
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Veterinary Orthobiologics Market, By Product:

o   Stem Cells

o   Platelet-rich Plasma (PRP)

o   Other

  • Veterinary Orthobiologics Market, By Animal:

o   Canine

o   Equine

o   Others

  • Veterinary Orthobiologics Market, By Application:

o   Osteoarthritis

o   Degenerative Joint Disease

o   Other

  • Veterinary Orthobiologics Market, By Delivery Mode:

o   Intra-muscular/Intra-lesional

o   Intra-articular

o   Others

  • Veterinary Orthobiologics Market, By End User:

o   Veterinary Hospitals

o   Veterinary Clinics

o   Others

  • Veterinary Orthobiologics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customizations:

Global Veterinary Orthobiologics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Veterinary Orthobiologics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Veterinary Orthobiologics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Product (Stem Cells, Platelet-rich Plasma (PRP), Other)

5.2.2.    By Animal (Canine, Equine, Others)

5.2.3.    By Application (Osteoarthritis, Degenerative Joint Disease, Other)

5.2.4.    By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others)

5.2.5.    By End User (Veterinary Hospitals, Veterinary Clinics, Others)

5.2.6.    By Region

5.2.7.    By Company (2023)

5.3.  Market Map

6.    North America Veterinary Orthobiologics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Product

6.2.2.    By Animal

6.2.3.    By Application

6.2.4.    By Delivery Mode

6.2.5.    By End User

6.2.6.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Veterinary Orthobiologics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Product

6.3.1.2.2.           By Animal

6.3.1.2.3.           By Application

6.3.1.2.4.           By Delivery Mode

6.3.1.2.5.           By End User

6.3.2.    Canada Veterinary Orthobiologics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Product

6.3.2.2.2.           By Animal

6.3.2.2.3.           By Application

6.3.2.2.4.           By Delivery Mode

6.3.2.2.5.           By End User

6.3.3.    Mexico Veterinary Orthobiologics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Product

6.3.3.2.2.           By Animal

6.3.3.2.3.           By Application

6.3.3.2.4.           By Delivery Mode

6.3.3.2.5.           By End User

7.    Europe Veterinary Orthobiologics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Product

7.2.2.    By Animal

7.2.3.    By Application

7.2.4.    By Delivery Mode

7.2.5.    By End User

7.2.6.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany Veterinary Orthobiologics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Product

7.3.1.2.2.           By Animal

7.3.1.2.3.           By Application

7.3.1.2.4.           By Delivery Mode

7.3.1.2.5.           By End User

7.3.2.    United Kingdom Veterinary Orthobiologics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Product

7.3.2.2.2.           By Animal

7.3.2.2.3.           By Application

7.3.2.2.4.           By Delivery Mode

7.3.2.2.5.           By End User

7.3.3.    Italy Veterinary Orthobiologics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Product

7.3.3.2.2.           By Animal

7.3.3.2.3.           By Application

7.3.3.2.4.           By Delivery Mode

7.3.3.2.5.           By End User

7.3.4.    France Veterinary Orthobiologics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Product

7.3.4.2.2.           By Animal

7.3.4.2.3.           By Application

7.3.4.2.4.           By Delivery Mode

7.3.4.2.5.           By End User

7.3.5.    Spain Veterinary Orthobiologics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Product

7.3.5.2.2.           By Animal

7.3.5.2.3.           By Application

7.3.5.2.4.           By Delivery Mode

7.3.5.2.5.           By End User

8.    Asia-Pacific Veterinary Orthobiologics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Product

8.2.2.    By Animal

8.2.3.    By Application

8.2.4.    By Delivery Mode

8.2.5.    By End User

8.2.6.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Veterinary Orthobiologics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Product

8.3.1.2.2.           By Animal

8.3.1.2.3.           By Application

8.3.1.2.4.           By Delivery Mode

8.3.1.2.5.           By End User

8.3.2.    India Veterinary Orthobiologics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Product

8.3.2.2.2.           By Animal

8.3.2.2.3.           By Application

8.3.2.2.4.           By Delivery Mode

8.3.2.2.5.           By End User

8.3.3.    Japan Veterinary Orthobiologics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Product

8.3.3.2.2.           By Animal

8.3.3.2.3.           By Application

8.3.3.2.4.           By Delivery Mode

8.3.3.2.5.           By End User

8.3.4.    South Korea Veterinary Orthobiologics Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Product

8.3.4.2.2.           By Animal

8.3.4.2.3.           By Application

8.3.4.2.4.           By Delivery Mode

8.3.4.2.5.           By End User

8.3.5.    Australia Veterinary Orthobiologics Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Product

8.3.5.2.2.           By Animal

8.3.5.2.3.           By Application

8.3.5.2.4.           By Delivery Mode

8.3.5.2.5.           By End User

9.    South America Veterinary Orthobiologics Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Product

9.2.2.    By Animal

9.2.3.    By Application

9.2.4.    By Delivery Mode

9.2.5.    By End User

9.2.6.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Veterinary Orthobiologics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Product

9.3.1.2.2.           By Animal

9.3.1.2.3.           By Application

9.3.1.2.4.           By Delivery Mode

9.3.1.2.5.           By End User

9.3.2.    Argentina Veterinary Orthobiologics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Product

9.3.2.2.2.           By Animal

9.3.2.2.3.           By Application

9.3.2.2.4.           By Delivery Mode

9.3.2.2.5.           By End User

9.3.3.    Colombia Veterinary Orthobiologics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Product

9.3.3.2.2.           By Animal

9.3.3.2.3.           By Application

9.3.3.2.4.           By Delivery Mode

9.3.3.2.5.           By End User

10. Middle East and Africa Veterinary Orthobiologics Market Outlook

10.1.   Market Size & Forecast        

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Product

10.2.2. By Animal

10.2.3. By Application

10.2.4. By Delivery Mode

10.2.5. By End User

10.2.6. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa Veterinary Orthobiologics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Product

10.3.1.2.2.         By Animal

10.3.1.2.3.         By Application

10.3.1.2.4.         By Delivery Mode

10.3.1.2.5.         By End User

10.3.2. Saudi Arabia Veterinary Orthobiologics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Product

10.3.2.2.2.         By Animal

10.3.2.2.3.         By Application

10.3.2.2.4.         By Delivery Mode

10.3.2.2.5.         By End User

10.3.3. UAE Veterinary Orthobiologics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Product

10.3.3.2.2.         By Animal

10.3.3.2.3.         By Application

10.3.3.2.4.         By Delivery Mode

10.3.3.2.5.         By End User

11. Market Dynamics

11.1.   Drivers

11.2.   Challenges

12. Market Trends & Developments

12.1.   Recent Developments

12.2.   Product Launches

12.3.   Mergers & Acquisitions

13. Global Veterinary Orthobiologics Market: SWOT Analysis

14. Competitive Landscape

14.1.   Zoetis Services LLC

14.1.1.       Business Overview

14.1.2.       Product & Service Offerings

14.1.3.       Financials (If Listed)

14.1.4.       Recent Developments

14.1.5.       Key Personnel

14.1.6.       SWOT Analysis

14.2.   Boehringer Ingelheim International GmbH

14.3.   Ardent Animal Health

14.4.   Enso Discoveries, LLC

14.5.   VetStem, Inc

14.6.   MEDREGO LLC

14.7.   Arthrex, Inc.

14.8.   Hilltop Biosciences

14.9.   Enovis Corporation

14.10.Dechra Pharmaceuticals Limited

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Veterinary Orthobiologics Market was estimated to be USD 689.85 Million in 2023.

down-arrow

Zoetis Services LLC, Boehringer Ingelheim International GmbH, Ardent Animal Health, Enso Discoveries, LLC, VetStem, Inc, MEDREGO LLC were the top key players in the Global Veterinary Orthobiologics Market in 2023.

down-arrow

High Cost of Treatments and Regulatory and Approval Challenges are the major challenges which restrict the growth of the Global Veterinary Orthobiologics Market.

down-arrow

Rising Incidence of Musculoskeletal Disorders and Technological Advancements in Regenerative Medicine are the major drivers for the Global Veterinary Orthobiologics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Veterinary Orthobiologics Market to Grow with a CAGR of 8.15% through 2029

Jul, 2024

Rising Incidence of Musculoskeletal Disorders and Increasing Pet Ownership and Humanization of Pets are expected to drive the Global Veterinary Orthobiologics Market growth in the forecast period, 20

Why Choose Us